SAN DIEGO, March 24, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (NasdaqGM:VICL - News) today announced that an independent Safety Monitoring Board (SMB) for the company’s Phase 3 AIMM trial of Allovectin-7(r) in patients with metastatic melanoma has completed the trial’s second scheduled safety analysis and recommended that the trial continue per the protocol. The trial is expected to complete enrollment of the planned 375 subjects by year-end 2009.
